- Live
- Attenuated
- Recombinant
Influenza Vaccine Market size was valued at USD 7.32 billion in 2023 and is poised to grow at a significant CAGR of 6.5% over 2024-2030. The market refers to the industry that encompasses the production, distribution, and sales of vaccines used for preventing influenza, commonly known as the flu. Influenza is a contagious respiratory illness caused by influenza viruses and can lead to severe complications and even death. Vaccination is a crucial preventive measure in reducing the incidence and severity of influenza infections. The influenza vaccine market is diverse, with various players including pharmaceutical companies, biotechnology firms, and government agencies involved in its development and distribution. These entities collaborate to develop and manufacture different types of influenza vaccines, such as trivalent, quadrivalent, and high-dose vaccines, targeting specific strains of the virus. Several trends shape the global influenza vaccine market.
Increased emphasis on improving the effectiveness and coverage of influenza vaccines, especially for high-risk populations like the elderly and individuals with chronic illnesses. This has led to the development of more advanced vaccine technologies and formulations. Additionally, technological advancements in vaccine delivery, such as the development of intranasal and microneedle-based vaccines, are gaining attention for their potential to enhance vaccine coverage and ease of administration. The global influenza vaccine market dynamics are driven by the need to prevent and control influenza infections. It is characterized by diverse players, ongoing technological advancements, and increasing demand for improved vaccine effectiveness and coverage. The market is expected to continue evolving to address emerging challenges and provide better protection against influenza viruses.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increasing awareness about the importance of influenza vaccination has led to a higher demand for vaccines around the globe. People are now more informed about the benefits of getting vaccinated against the flu, leading to increased uptake of vaccines. Governments and healthcare organizations have played a significant role in promoting vaccination campaigns, emphasizing the prevention of seasonal outbreaks and potential pandemics. This heightened awareness has resulted in a surge in demand for the influenza vaccines market worldwide, as individuals recognize the value of protecting themselves and others from influenza infections.
Influenza, commonly known as flu, is a contagious respiratory infection or illness caused by influenza viruses. The influenza vaccine protects a person from getting the flu.
The major factor for the growth of the Influenza Vaccine Market is a high prevalence of influenza, an increase in government focuses on immunization programs, emerging vaccines, and technological progress in vaccine administration.
Astrazeneca Plc (Astrazeneca), Biodiem, Csl Limited (Seqirus GmbH), Emergent Biosolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., Glaxosmithkline Plc.
1. Executive Summary |
2. Global Influenza Vaccines Market Introduction |
2.1. Global Influenza Vaccines Market - Taxonomy |
2.2. Global Influenza Vaccines Market - Definitions |
2.2.1. Product Type |
2.2.2. Route of Administration |
2.2.3. Type |
2.2.4. Distribution Channel |
2.2.5. Region |
3. Global Influenza Vaccines Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Key Developments |
3.6. M&A Activities |
3.7. Competition Assessment |
3.8. New Product Launches |
4. Global Influenza Vaccines Market By Product Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
4.1. Live |
4.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.1.3. Market Opportunity Analysis |
4.2. Attenuated |
4.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.2.3. Market Opportunity Analysis |
4.3. Recombinant |
4.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
4.3.3. Market Opportunity Analysis |
5. Global Influenza Vaccines Market By Route of Administration, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Intranasal |
5 1 1 Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Injection |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Influenza Vaccines Market By Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Monvalent |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Trivalent |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Quadrivalent |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Influenza Vaccines Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Hospital and Retail Pharmacies |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Government Agenices |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Influenza Vaccines Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. MEA |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Influenza Vaccines Market - Opportunity Analysis Index, By Route of Administration, Product Type, Type, Distribution Channel and Region, 2024-2030 |
9. North America Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Product Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Live |
9.1.2. Attenuated |
9.1.3. Recombinant |
9.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Intranasal |
9.2.2. Injection |
9.3. Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Monvalent |
9.3.2. Trivalent |
9.3.3. Quadrivalent |
9.4. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1. Hospital and Retail Pharmacies |
9.4.2. Government Agenices |
9.4.3. Others |
9.5. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.5.1. USA |
9.5.2. Canada |
10. Europe Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Product Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Live |
10.1.2. Attenuated |
10.1.3. Recombinant |
10.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Intranasal |
10.2.2. Injection |
10.3. Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Monvalent |
10.3.2. Trivalent |
10.3.3. Quadrivalent |
10.4. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1. Hospital and Retail Pharmacies |
10.4.2. Government Agenices |
10.4.3. Others |
10.5. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1. Germany |
10.5.2. France |
10.5.3. Italy |
10.5.4. Spain |
10.5.5. Rest of Europe |
11. Asia Pacific Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Product Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Live |
11.1.2. Attenuated |
11.1.3. Recombinant |
11.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Intranasal |
11.2.2. Injection |
11.3. Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Monvalent |
11.3.2. Trivalent |
11.3.3. Quadrivalent |
11.4. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1. Hospital and Retail Pharmacies |
11.4.2. Government Agenices |
11.4.3. Others |
11.5. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1. China |
11.5.2. India |
11.5.3. Korea |
11.5.4. Japan |
11.5.5. Rest of APAC |
12. Latin America Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Product Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Live |
12.1.2. Attenuated |
12.1.3. Recombinant |
12.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Intranasal |
12.2.2. Injection |
12.3. Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Monvalent |
12.3.2. Trivalent |
12.3.3. Quadrivalent |
12.4. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1. Hospital and Retail Pharmacies |
12.4.2. Government Agenices |
12.4.3. Others |
12.5. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1. Brazil |
12.5.2. Mexico |
12.5.3. Argentina |
12.5.4. Rest of LA |
13. MEA Influenza Vaccines Market, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Product Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Live |
13.1.2. Attenuated |
13.1.3. Recombinant |
13.2. Route of Administration Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Intranasal |
13.2.2. Injection |
13.3. Type Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Monvalent |
13.3.2. Trivalent |
13.3.3. Quadrivalent |
13.4. Distribution Channel Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1. Hospital and Retail Pharmacies |
13.4.2. Government Agenices |
13.4.3. Others |
13.5. Country Analysis, 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1. GCC Countries |
13.5.2. South Africa |
13.5.3. Rest of MEA |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Sanofi |
14.2.2. GSK |
14.2.3. Serum Institute of India |
14.2.4. Abbott |
14.2.5. AstraZeneca |
14.2.6. Seqirus |
14.2.7. Sinovac |
14.2.8. Novovax |
14.2.9. Pfizer |
14.2.10. Moderna |
14.2.11. Daiichi Sankyo |
14.2.12. CureVac |
14.2.13. Ansun Biopharma, Inc. |
14.2.14. Medigen Vaccine Biologics Corp |
14.2.15. LiteVax BV |
14.2.16. ENA Respiratory Pty Ltd |
15. Research Methodology |
16. Key Assumptions and Acronyms |